Articles

May 14, 2018- Medical Marijuana: Efficacy, Toxicity, and Legality

Medical marijuana can exist in a variety of formulations such as dried flowers, resins, extracts and oils. It’s legalization and use for medical purposes is still a developing issue and the perspectives of many health care providers is also following the same path. Medical marijuana can be used to ease chronic pain, chemotherapy-induced nausea and…

Read More

June 28, 2018 – Molecular testing in Metastatic Gastric/GEJ Cancer

DDF’s Scientific and Medical Advisory Board Chair, David Ilson, MD, PhD, explains that when it comes to a patient with metastatic disease molecular testing does have an impact on choices of therapy. More specifically HER2 testing is a common in patients with metastatic disease. If a patient is HER2-positive, then trastuzumab is included as part…

Read More

June 21, 2018 – TAS-102 Prolongs Survival in Phase III Gastric Cancer Study

According to a recent study, TAS-102 (trifluridine/tipiracil; Lonsurf) provided a 31% reduction in the risk of death for patients with heavily pretreated metastatic or advanced gastric cancer that received the drug compared to patients who received a placebo. The median overall survival time was 5.7 months for patients who received TAS-102 compared with 3.6 months…

Read More

June 18, 2018 – Adjuvant Chemotherapy Advances Boost Outcomes in GI Malignancies

In gastric cancer, results from a FLOT4 clinical trial suggest that the FLOT (fluorouracil/leucovorin, oxaliplatin, and docetaxel [Taxotere]) regimen should be the primary adjuvant treatment in gastric cancer over epirubicin/cisplatin/fluorouracil (ECF) or epirubicin/cisplatin/oxaliplatin (ECX). The trial showed that overall survival was longer for patients assigned to FLOT compared with ECF/ ECX (50 vs 35 months)…

Read More

June 16, 2018 – Endoscopic Surveillance Detects Early Gastric Cancer

A study found that endoscopic surveillance can detect gastric cancer at an early curable stage. 279 patients (previous diagnosed with either atrophic gastritis, intestinal metaplasia, or dysplasia) underwent at least one surveillance endoscopy. 84% of the patients were Caucasian. The first surveillance endoscopy was conducted after a mean interval of 35 months with a mean…

Read More

June 12, 2018 – Risk of Diabetes May Increase After Cancer Diagnosis

Diabetes is the main cause of cancer-unrelated mortality among cancer survivors. Numerous studies have suggested that diabetes increases risk for developing cancer. A recent South Korean study found that having cancer itself also increases risk for developing diabetes. Researchers followed 494,189 patients between ages 20 and 70 without diabetes and cancer for a median of…

Read More

June 12, 2018 – Futuristic gene-editing technology may cause cancer

Two studies have suggested that successful gene editing with CRISPR Cas9 (to cure genetic diseases) may be associated with an increased risk of developing cancer. This is because the edit may indicate that the modified cell lacks the cancer-suppressing protein, p53. P53 acts as the body’s cellular “first aid” kit and also causes some CRISPR…

Read More

June 07, 2018 – Helicobacter pylori and Prevention of Gastric Cancer

This article consists of two letters to the editor regarding a clinical trial in which the relationship between Helicobacter Pylori eradication and rate of new tumor occurrences unrelated to gastric cancer (metachronous gastric cancer) and grade of corpus atrophy was examined. In a potential trial conducted in South Korea, early gastric cancer patients who received…

Read More